hsa-mir-340: Hsa-mir-340 is a microRNA that has been found to be downregulated in the low bone mineral density (BMD) group and is correlated with the expression level of its target gene PDPK1 [PMC4577125]. In prostate cancer cell lysates, hsa-mir-340 was used in a DNA pull-down assay to target and bind with streptavidin-containing magnetic beads [PMC7884413]. However, the reduced expression of hsa-mir-340 did not significantly improve cisplatin cytotoxicity, while increased expression of hsa-miR-302b enhanced cisplatin cytotoxicity [PMC3590172]. In dilated cardiomyopathy (DCM) samples, hsa-mir-340 was found to be significantly differentially regulated compared to non-failing control samples [PMC4118176]. Additionally, hsa-mir-340 was found to be upregulated in DCM samples along with other miRNAs such as hsa-miR-19b and hsa-miR-302 [PMC4118176]. Higher expression of hsa-mir-340 was associated with shorter overall survival time in endometrial cancer patients [PMC9200351]. In the context of COVID-19 interaction, hsa-mir-340 was among the significant miRNAs identified in the TF–miRNA network analysis [PMC9429819]. Hsa-mir-340 has also been associated with mitochondria in HEK293 cells along with other miRNAs such as hsa-miR-25 and hsa-miR-423-5p [PMC3439422]. Complementary sequences were detected between COMMD6 and hsa-mir-340 as well as between lncRNA TEX41 and hsa-mir 340 [PMC6889128][PMC6889128].